A multidisciplinary team of researchers from the Sheffield Institute of Translational Neuroscience (SITraN), in collaboration with scientists from the University of York, have recently released results from a study that supports the fast-tracking of the drug ursodeoxycholic acid (UDCA), which has already been in use for decades to…
News
Recently, researchers from the National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS) released results from X-ray crystalography analysis of the the neuropeptide hormone neurotensin, which has been shown to be involved in Parkinson’s Disease (PD).  Their research resulted in the first images showing how…
The National Parkinson Foundation, originally founded in 1957 and committed to helping patients diagnosed with Parkinson’s disease live a better, fuller life, has just announced the official relaunch of their website, featuring a brand new design that facilitates visitors’ awareness and knowledge of the disease. The website now offers free…
News
Study Reveals the Reason Underlying Dissimilar Outcomes With Antagonist Drugs in Brain Disorders
A new study led by researchers at the University of Barcelona in Spain recently revealed the reason behind discrepant outcomes when administering antagonist drugs for brain disorders. The study was published in the journal Proceedings of the National Academy of Sciences (PNAS) and is entitled “…
Parkinson’s disease is still the second most common neurodegenerative disorder affecting millions of people worldwide. A multidisciplinary team of researchers from UCL, the University of Cambridge and the University of Sheffield, have recently published a study in Nature Neuroscience linking a Parkinson’s disease-causing mutation in the Fbx07 gene…
Neurodegenerative diseases correspond to a range of debilitating conditions that primarily result in the degeneration and/or death of brain and spinal cord neurons. Parkinson’s disease is one example of a progressive neurodegenerative disorder that develops gradually, with patients usually experiencing the first symptoms around the age of 60 or older.
Recently, a group of researchers from the Buck Institute for Age Research in Novato, California released study results in which they found that low-dose lithium reduced involuntary motor movements – the troubling side effect of the medication most commonly used to treat Parkinson’s disease (PD). The study, entitled, “…
A multidisciplinary team of researchers from the London School of Hygiene & Tropical Medicine (LSHTM), have recently released results from a retrospective study showing that Glitazone, a type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease (PD).  The study, entitled, “…
New encouraging data on novel therapeutic drugs targeting components affected in several brain diseases linked to dementia have been recently presented at the Alzheimer’s Association International Conference 2015 (AAIC 2015) in Washington, D.C. The brain diseases considered included Parkinson’s disease, Alzheimer’s disease and Lewy Body dementia. All three conditions…
In a recent pilot study published in the journal Digital Health a team of researchers are testing new technologies for Parkinson’s disease (PD) which may influence clinical research in personal genetic testing to better diagnose and potentially treat PD. “These findings demonstrate that remote recruitment and conduct…
Recent Posts
- MJFF grants totaling $7.6M will help Casma develop Parkinson’s therapy
- Planning is key when traveling with Parkinson’s disease
- I’m an optimist, but sometimes Parkinson’s fatigue is too much
- New smartphone platform helps doctors track Parkinson’s symptoms
- Camping can be a wonderful activity for those of us living with Parkinson’s